Xenon Pharmaceuticals announced it will present five abstracts at the 2026 American Academy of Neurology (AAN) Annual Meeting, including late-breaking Phase 3 results and 48-month long-term data for azetukalner, a novel drug for focal onset seizures. The presentations also cover real-world epilepsy data on treatment burdens and a preclinical program for Dravet syndrome. These updates highlight Xenon's progress in developing azetukalner and other therapies, with potential impacts on epilepsy treatment options. The event takes place April 18-22, 2026, in Chicago.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
